Cardlytics (NASDAQ:CDLX) Releases Earnings Results, Misses Expectations By $0.08 EPS

Cardlytics (NASDAQ:CDLX) announced its quarterly earnings results on Wednesday. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.08), Zacks reports. The firm had revenue of $56.10 million for the quarter, compared to analysts’ expectations of $54.46 million. Cardlytics had a negative return on equity of 235.70% and a negative net margin of 44.12%.

Here are the key takeaways from Cardlytics’ conference call:

• Cardlytics says its 2025 reset delivered discipline and tech modernization — reporting full-year Adjusted EBITDA of $10.1M, Q4 Adjusted EBITDA of $8.5M, faster feature delivery (+20%) and lower infrastructure costs (-40%).
• The company ended its Bank of America relationship and faces content restrictions from a large FI, which the firm says is the primary driver of weak Q1 2026 guidance (billings down ~41%–35% YoY) and an expected negative Adjusted EBITDA of -$7.5M to -$3.5M.
• Management highlights strong advertiser traction — particularly in grocery, convenience and fashion/luxury — with Q4 U.K. revenue up >35% YoY, a 60% QoQ increase in new business wins, and large spend increases from key advertisers.
• The planned sale of Bridg to PAR Technology is expected to close this month and, per management, will bolster liquidity (they intend to liquidate received PAR shares to pay down the credit facility) and eliminate non-core costs.

Cardlytics Trading Down 9.8%

Shares of Cardlytics stock traded down $0.09 during mid-day trading on Thursday, hitting $0.81. 612,490 shares of the stock were exchanged, compared to its average volume of 775,361. The stock has a market capitalization of $43.87 million, a price-to-earnings ratio of -0.38, a price-to-earnings-growth ratio of 0.13 and a beta of 1.03. Cardlytics has a twelve month low of $0.75 and a twelve month high of $3.28. The company has a current ratio of 1.14, a quick ratio of 1.14 and a debt-to-equity ratio of 2.87. The company has a 50-day simple moving average of $1.06 and a 200 day simple moving average of $1.37.

Analysts Set New Price Targets

CDLX has been the topic of several research reports. Wall Street Zen lowered Cardlytics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Bank of America reissued an “underperform” rating on shares of Cardlytics in a research note on Thursday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cardlytics in a research report on Monday, December 29th. Three investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Cardlytics presently has a consensus rating of “Reduce” and an average target price of $2.25.

Insider Activity

In related news, CEO Amit Gupta sold 52,049 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $0.90, for a total transaction of $46,844.10. Following the sale, the chief executive officer owned 704,803 shares in the company, valued at approximately $634,322.70. This trade represents a 6.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 117,875 shares of company stock worth $113,022 over the last quarter. Corporate insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new stake in shares of Cardlytics in the fourth quarter valued at $39,000. Qube Research & Technologies Ltd acquired a new stake in Cardlytics in the 3rd quarter worth about $55,000. Marshall Wace LLP acquired a new stake in Cardlytics in the 2nd quarter worth about $59,000. Renaissance Technologies LLC purchased a new stake in Cardlytics in the 4th quarter valued at about $62,000. Finally, Barclays PLC increased its stake in shares of Cardlytics by 31,167.6% during the 4th quarter. Barclays PLC now owns 55,969 shares of the company’s stock valued at $64,000 after acquiring an additional 55,790 shares during the last quarter. Hedge funds and other institutional investors own 68.10% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence and marketing platform that connects advertisers with consumers through bank and credit card transaction data. The company partners with financial institutions to analyze anonymized purchase information, enabling brands to deliver highly targeted offers and rewards directly to customers’ online and mobile banking channels. By leveraging real-time insights into consumer spending habits, Cardlytics helps marketers optimize campaign performance and measure return on ad spend more accurately than traditional digital advertising methods.

At the core of Cardlytics’ offering is its proprietary purchase intelligence engine, which aggregates and anonymizes transaction data from partner banks and credit unions.